

OPPI Coverage Dossier

August 2025

INDEX

S.no	Date	Publication	Edition	Link
Online				
1	14 August	CNBC TV18	Online	Rising NCDs: Why the future demands a new era of pharma innovation
2	18 August	Express Pharma	Online	Anil Matai, Director General of OPPI, on the Future of Indian Pharma: From Product Provider to Health Partner”.

ONLINE

Publication	CNBC TV18
Date	14 August
Edition	Online
Headline	Rising NCDs: Why the future demands a new era of pharma innovation

Rising NCDs: Why the future demands a new era of pharma innovation



[cnbctv18.com/access/opinion/rising-ncds-future-needs-new-era-of-pharma-innovation-atypical-pattern-of-diseases-cancer-cardiovascular-disease-diabetes-oppi-19653211.htm](https://www.cnbctv18.com/access/opinion/rising-ncds-future-needs-new-era-of-pharma-innovation-atypical-pattern-of-diseases-cancer-cardiovascular-disease-diabetes-oppi-19653211.htm)

Anil Matai

August 14, 2025







Non-communicable diseases (NCDs) have now overtaken infectious diseases as the leading cause of illness and death in India. An estimated 5.8 million Indians die from these diseases each year; approximately one in four Indians faces the risk of dying from an NCD before reaching the age of 70. The most prevalent among this disease segment includes cardiovascular diseases (CVDs), diabetes, cancers, obesity, and chronic respiratory conditions, each of which brings with it a significant burden of morbidity and long-term care.

These conditions are no longer confined to urban or affluent populations, they are increasingly affecting rural areas and economically vulnerable groups, creating a widespread health crisis.

India's rapidly evolving demographic profile characterised by an aging population, accelerated urbanisation, and shifting lifestyle patterns is reshaping the country's healthcare needs, with sedentary behaviors, unhealthy diets, rising stress levels, and pollution contributing to a growing burden of NCDs. This shift has not only expanded the number of people at risk but also identified the types of diseases being diagnosed across age groups and geographies.

Publication	Express Pharma
Date	18 August
Edition	Online
Headline	Anil Matai, Director General of OPPI, on the Future of Indian Pharma: From Product Provider to Health Partner”.

[HOME](#)
[COVER STORY](#)
[FEATURES](#)
[SPECIALS](#)
[GUEST BLOGS](#)
[INTERVIEWS](#)
[EDITOR'S NOTE](#)
[EVENTS](#)
[VIDEOS](#)

[DRUG APPROVALS](#)
[NUTRACEUTICALS](#)
[PHARMA IT](#)
[POLICIES](#)
[TECHNOLOGY](#)
[LOGISTICS](#)
[HR](#)
[BIOTECH](#)
[STARTUP CORNER](#)
[BUSINESS STRA](#)

Home > Videos > Expert Speak > Anil Matai, Director General of OPPI, on the Future of Indian Pharma: From Product Provider to Health Partner



Anil Matai, Director General of OPPI, on the Future of Indian Pharma: From Product Provider to Health Partner


Regulatory Watch

By EP News Bureau — On Aug 18, 2025

[Share](#)
[Email](#)
[in](#)
[Twitter](#)
[f](#)

[EXPERT SPEAK](#)
[REGULATORY WATCH](#)

 6
  0



REGULATORY WATCH

The next challenge is how do we really balance innovation and accessibility in a country like ours, which is still to a large extent self pay.

